Resources from the same session
Introduction
Presenter: Giuseppe Curigliano
Session: ESMO Colloquium supported by Eli Lilly and Company: Precision Medicine Implementation in the Clinic: RET as a potential target in cancer treatment
Resources:
Slides
Webcast
Introduction to RET mutations and fusions and their incidence for potential use as target in cancer treatment
Presenter: Alexander Drilon
Session: ESMO Colloquium supported by Eli Lilly and Company: Precision Medicine Implementation in the Clinic: RET as a potential target in cancer treatment
Resources:
Slides
Webcast
RET alterations in Thyroid carcinomas: Results and recent update
Presenter: Lori Wirth
Session: ESMO Colloquium supported by Eli Lilly and Company: Precision Medicine Implementation in the Clinic: RET as a potential target in cancer treatment
Resources:
Slides
Webcast
RET determination: Present recommendation of the ESMO Precision Medicine working group
Presenter: Giuseppe Curigliano
Session: ESMO Colloquium supported by Eli Lilly and Company: Precision Medicine Implementation in the Clinic: RET as a potential target in cancer treatment
Resources:
Slides
Webcast
Conclusion: Is RET targeting ready for an agnostic use?
Presenter: Alexander Drilon
Session: ESMO Colloquium supported by Eli Lilly and Company: Precision Medicine Implementation in the Clinic: RET as a potential target in cancer treatment
Resources:
Slides
Webcast
Live Q&A
Presenter: Alexander Drilon
Session: ESMO Colloquium supported by Eli Lilly and Company: Precision Medicine Implementation in the Clinic: RET as a potential target in cancer treatment
Resources:
Webcast